Megaport Expands to 14 More Data Centres Across Europe and Strengthens Operations Through Strategic Partnerships
Megaport Limited (ASX: MP1) (“Megaport”), the global leading Network as a Service (NaaS) provider, is proud to announce its expansion across Europe with 14 new data centre locations across seven countries, as well as strategic partnerships with Portus Data Centers, NorthC Data Centers, and Sipartech in key locations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241015455053/en/
Megaport expands to 14 more data centres across Europe and strengthens operations through strategic partnerships (Graphic: Business Wire)
These new Points of Presence (PoPs) and partnerships significantly extend Megaport’s service reach, allowing customers to connect to a much wider ecosystem of service providers and data centres across Europe via a high-performance, scalable network underlay.
Megaport has collaborated with data centre operator Portus Data Centers to extend its reach in Germany. By deploying a new Megaport PoP in Munich, joint customers now benefit from wider reach and enhanced connectivity capabilities in Central Europe.
Megaport has also strengthened its partnership with NorthC Data Centers in the Netherlands by launching a second Point of Presence (PoP) at NorthC's data centre in Almere, located in the Amsterdam Metropolitan Area. Megaport services have been established at NorthC's data centre in Oude Meer for several years, making the Almere PoP the latest addition to their expanding presence in the Amsterdam Metropolitan Area. This expansion is part of a broader series of joint initiatives with NorthC Data Centers to enhance connectivity and service availability nationwide.
Additionally, Megaport has finalised its partnership with Sipartech, a provider of high-speed connectivity solutions. With its dense optical network in France and other European capital cities, Sipartech supports last-mile connectivity for Megaport customers in Western Europe.
These key partnerships and 14 total new locations now make it even easier for joint customers to modernise their network connectivity and connect to leading cloud service providers across Europe.
“Expanding to so many new European locations alongside such exceptional partners allows us to bring the network revolution further into Europe, giving new customers the ability to supercharge their business and build connections in less than 60 seconds,” said Michael Reid, CEO of Megaport.
“We’re thrilled to be working with Megaport in our Tier IV data centre in Munich to expand their global reach on our high-performance data centre infrastructure. Now, we can provide more customers in Germany with their wide range of connectivity solutions to drive business growth,” said Adriaan Oosthoek, Chairman at Portus Data Centers.
“The addition of Megaport's new Point of Presence to our Almere data centre means our clients now have greater access to a diverse range of connectivity and cloud services, ensuring they remain at the forefront of innovation and digital transformation,” said Vincent Wammes, Director International Alliances and Accounts at NorthC Data Centers.
“We are thrilled to partner with Megaport. Together, we share a common vision: to elevate the experience of our clients through reliable and high-performance connectivity. This partnership enables us to deliver even more innovative and tailored connectivity solutions to our customers in France, Spain, Italy, and beyond,” said Julien Santina, President and Founder at Sipartech.
Megaport's growing customer base includes leading companies like Veolia Water, which has leveraged these new locations and partners to improve its European operations.
“With their growing partner ecosystem, using Megaport has enabled us to diversify our multicloud and enhance our operations through multi-data centre access across Europe,” said Vincent Lauriat, Chief Technology Officer and Deputy Chief Information Officer at Veolia Water. “As a result of implementing their reliable and resilient connectivity, we’ve seen a noticeable increase in customer satisfaction and revenue generation. They are a trusted partner.”
For more information about Megaport’s European expansion, visit megaport.com/new-locations.
About Megaport
Megaport is changing how businesses connect their infrastructure, with one smart and simple platform to manage every connection. Build secure, scalable, and agile networks in just a few clicks, accessing global endpoints and creating private paths in minutes. Trusted by the world’s leading companies, Megaport partners with global service providers, DC operators, systems integrators, and managed services companies, and operates in 860+ enabled locations worldwide. Megaport is ISO/IEC 27001 certified. Join the network revolution at megaport.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241015455053/en/
Contacts
Media Enquiries
Adam Hennessy, Head of Marketing - Brand & Communications, Megaport
Phone: +61 7 3088 7400
media@megaport.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom